Mario P Colombo
Overview
Explore the profile of Mario P Colombo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
143
Citations
8560
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Castagnoli L, Franceschini A, Cancila V, Dugo M, Bigliardi M, Chiodoni C, et al.
J Exp Clin Cancer Res
. 2025 Jan;
44(1):19.
PMID: 39833955
Background: Growing evidence shows that the reprogramming of fatty acid (FA) metabolism plays a key role in HER2-positive (HER2 +) breast cancer (BC) aggressiveness, therapy resistance and cancer stemness. In...
2.
Sulsenti R, Scialpi G, Frossi B, Botti L, Ferri R, Tripodi I, et al.
Cancer Immunol Res
. 2024 Jun;
12(9):1147-1169.
PMID: 38869181
Neuroendocrine prostate cancer (NEPC) is an aggressive form of prostate cancer that emerges as tumors become resistant to hormone therapies or, rarely, arises de novo in treatment-naïve patients. The urgent...
3.
Fischetti I, Botti L, Sulsenti R, Cancila V, Enriquez C, Ferri R, et al.
Epigenomics
. 2024 Mar;
PMID: 38530086
Castration-resistant prostate cancer (CRPC) eventually becomes resistant to androgen receptor pathway inhibitors like enzalutamide. Immunotherapy also fails in CRPC. We propose a new approach to simultaneously revert enzalutamide resistance and...
4.
Bassani B, Simonetti G, Cancila V, Fiorino A, Ciciarello M, Piva A, et al.
Cell Rep
. 2024 Feb;
43(2):113794.
PMID: 38363677
Acute myeloid leukemia (AML) progression is influenced by immune suppression induced by leukemia cells. ZEB1, a critical transcription factor in epithelial-to-mesenchymal transition, demonstrates immune regulatory functions in AML. Silencing ZEB1...
5.
Cascini C, Ratti C, Botti L, Parma B, Cancila V, Salvaggio A, et al.
J Exp Clin Cancer Res
. 2023 Jun;
42(1):154.
PMID: 37365634
Background: Osteosarcoma (OS) is the most common primary bone tumor in children and adolescent. Surgery and multidrug chemotherapy are the standard of treatment achieving 60-70% of event-free survival for localized...
6.
Cioni B, Ratti S, Piva A, Tripodi I, Milani M, Menichetti F, et al.
Mol Cancer Res
. 2023 Mar;
21(6):614-627.
PMID: 36867680
Implications: Our findings identify JMJD6 as a determinant of breast cancer aggressiveness and provide the rationale for the development of inhibitory molecules to reduce disease progression also through the remodeling...
7.
Rizzello C, Cancila V, Sangaletti S, Botti L, Ratti C, Milani M, et al.
Mol Cancer
. 2022 Dec;
21(1):215.
PMID: 36503430
Background: Autoimmune disorders, including Systemic Lupus Erythematosus (SLE), are associated with increased incidence of hematological malignancies. The matricellular protein osteopontin (OPN) has been linked to SLE pathogenesis, as SLE patients...
8.
Perrone M, Chiodoni C, Lecchi M, Botti L, Bassani B, Piva A, et al.
Cancer Res
. 2022 Nov;
83(1):117-129.
PMID: 36318106
Cancer is a systemic disease able to reprogram the bone marrow (BM) niche towards a protumorigenic state. The impact of cancer on specific BM subpopulations can qualitatively differ according to...
9.
Cortellino S, Raveane A, Chiodoni C, Delfanti G, Pisati F, Spagnolo V, et al.
Cell Rep
. 2022 Aug;
40(8):111256.
PMID: 36001966
Immunotherapy is improving the prognosis and survival of cancer patients, but despite encouraging outcomes in different cancers, the majority of tumors are resistant to it, and the immunotherapy combinations are...
10.
Bellenghi M, Talarico G, Botti L, Puglisi R, Tabolacci C, Portararo P, et al.
Oncogene
. 2022 Jul;
41(34):4055-4065.
PMID: 35851846
Dysregulated fatty acid metabolism interacts with oncogenic signals, thereby worsening tumor aggressiveness. The stearoyl-CoA desaturating enzymes, SCD1 and SCD5, convert of saturated fatty acids to monounsaturated fatty acids. While SCD1...